{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/0d5e67e2\"></iframe>","width":"100%","height":180,"duration":538,"description":"Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.\nSpeaker 3: (00:32)\n Would you tell us a little bit about yourself and your history with this testing?\n \nSpeaker 3: (01:25)\n Would you tell us a little more about this assay?\n \nSpeaker 3: (04:57)\n Which patients should have this testing and when should it be performed? \n \nSpeaker 3: (05:30)\n What alternative tests exist and how do they compare?\n \nSpeaker 3: (06:28)\n How are the results used in patient care?","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}